"Studies were done in vivo (within the living) models of blood cancers and demonstrated that the drug removed malignant cells from the bloodstream, while allowing normal healthy blood cells to grow, thus differentiating CX-5461 from genotoxic treatments. Targeting cancer's dependence upon Pol I to trigger cancer-specific activation of p53 signifies an entirely new approach to cancer therapy."
Any indications on how CX-5461 will work on CML in specific?
"The trial will be open for both lymphomas and leukaemias that have not responded optimally to other treatments," Professor McArthur said.
"Our initial studies have focused on cancers that are hard to treat, because it's a real unmet need there and patients with those cancers desperately need new treatments, which is why we're focused initially on that area."
I guess CML does not fall into the hard to treat category, except of course for those who does not respond to treatment with standard tki`s.
I hope some "hard to treat" CML`ers will get the chance to join the trial.
Also, would CX-5461 be considered a treatment like a tki, or is it in more of a cure category?
I guess its too early to tell really, but if anyone has more knowledge on the subject, please share